Theragnostics Announces that its Radiotherapeutic for Treatment of Glioblastoma Multiforme has been Awarded UK’s MHRA Innovation Passport
- Promising non-clinical results support Phase 1 clinical study in recurrent GBM
- Commitment to ensuring I-123 PARPi is available to treat the unmet medical need of patients diagnosed with primary and recurrent GBM
LONDON, UK, 10 February 2022 – Theragnostics, which is developing radiopharmaceuticals for imaging and treatment of cancer, today announces that its novel I-123 PARPi (THG-009) therapeutic agent has been awarded an Innovation Passport by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of primary and recurrent Glioblastoma Multiforme (GBM). This is provided under the MHRA’s Innovative Licensing and Access Pathway (ILAP) which was launched in January 2021 to accelerate development and access to innovative medicines in the UK.
